New Lyme Disease Vaccine Shows Promise in Phase 3 Trial

A significant breakthrough in medical research occurred in March 2026, as Pfizer and Valneva announced the Phase 3 results for their Lyme disease vaccine candidate, VLA15.

orgPfizer

orgValneva

conceptLyme disease

techVLA15

Lyme disease is the most common vector-borne illness in the Northern Hemisphere, yet there is currently no approved vaccine available for human use.

conceptLyme disease

locationNorthern Hemisphere

The VALOR clinical trial tested the vaccine's efficacy in nearly 9,500 participants across North America and Europe.

eventVALOR

locationNorth America

locationEurope

🎉

End of article

You read 3 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary way VLA15 protects humans from Lyme disease?

It creates a permanent skin barrier against tick bites.

It destroys the tick's salivary glands instantly.

It produces antibodies that neutralize bacteria inside the tick's gut.

Reveal Answer

✓

Correct Choice

It produces antibodies that neutralize bacteria inside the tick's gut.

Why did the trial narrowly miss its primary statistical endpoint?

The vaccine was found to be ineffective in children.

There were fewer Lyme disease cases than researchers anticipated.

Too many participants dropped out due to side effects.

Reveal Answer

✓

Correct Choice

There were fewer Lyme disease cases than researchers anticipated.

What happened to the previous Lyme disease vaccine, LYMERix?

It was banned by the FDA due to severe safety risks.

It was discontinued in 2002 due to low public demand and concerns.

It was never approved for public use by authorities.

Reveal Answer

✓

Correct Choice

It was discontinued in 2002 due to low public demand and concerns.

Which of these statements about the VLA15 trial is true?

The trial failed to reach a secondary analysis threshold.

The trial involved participants from North America and Europe.

The trial was completed in under six months.

Reveal Answer

✓

Correct Choice

The trial involved participants from North America and Europe.

How many doses were required in the VALOR trial schedule?

Four doses.

Six doses.

Two doses.

Reveal Answer

✓

Correct Choice

Four doses.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play